External validation of prognostic and predictive gene signatures in head and neck cancer patients
Fossen, E. I. F.; Moreira-Soares, M.; LeBlanc, M.; Frigessi, A.; Hovig, E.; Lopez-Perez, L.; Estevez-Priego, E.; Hernandez, L.; Cabrera-Umpierrez, M. F.; Fico, G.; Tinhofer, I.; Sachse, V.; Scheckenbach, K.; Le Tourneau, C.; Kamal, M.; Thomas, S.; Pring, M.; Licitra, L.; De Cecco, L.; Cavalieri, S.
Show abstract
Head and neck squamous cell carcinomas (HNSCC) are aggressive and heterogenous tumors with a high fatality rate. Many gene signatures (GS) have been developed with both prognostic and predictive significance. We aimed to externally validate five published GS in a large European collection of HNSCC patients. Gene expression from 1097 treatment-naive HNSCC patients primary tumors was used to calculate scores for the five GS. Cox proportional hazard models were used to test the association between both 2-year overall survival and 2-year disease-free survival and the signature scores. The predictive role of GS was validated by comparing survival associations in patients receiving specific treatment (i.e., radiotherapy, systemic treatment) versus those who did not. We successfully externally validated all 5 GS, including two prognostic signatures, one signature as prognostic and predictive of sensitivity to systemic treatment, while signatures for cisplatin-sensitivity and radiosensitivity were validated as prognostic only.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Predicting immunotherapy response in advanced bladder cancer: a meta-analysis of six independent cohorts 94%
- Adjuvant nivolumab, capecitabine or the combination in patients with residual triple-negative breast cancer: the OXEL randomized phase II study 93%
- Tumour gene expression signature in primary melanoma predicts long-term outcomes: A prospective multicentre study 93%
Similar papers in this journal
Similar papers in this journal
- Clinical activity of Mitogen-Activated Protein Kinase (MAPK) inhibitors in patients with MAP2K1 (MEK1)-mutated metastatic cancers 93%
- Normalized LST is an efficient biomarker for homologous recombination deficiency and Olaparib response in ovarian carcinoma 93%
- An Evidenced-Based Prior for Estimating the Treatment Effect of Phase III Randomized Trials in Oncology 92%
Similar papers in this journal
- Indole 3-acetate and response to therapy in borderline resectable or locally advanced pancreatic cancer 91%
- Analysis of Mutational Profile of Hypopharyngeal and Laryngeal Head and Neck Cancers Identifies KMT2C as a Potential Tumor Suppressor 91%
- Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes 91%
Similar papers in this journal
- The French Early Breast Cancer Cohort (FRESH): a resource for breast cancer research and evaluations of oncology practices based on the French National Healthcare System Database (SNDS) 93%
- NDRG1 expression is an independent prognostic factor in inflammatory breast cancer 93%
- Trends in Phase II trials for cancer therapies 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.